XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study

Author： Rosati Gerardo   Avallone Antonio   Aprile Giuseppe   Butera Alfredo   Reggiardo Giorgio   Bilancia Domenico  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.71, Iss.1, 2013-01, pp. : 257-264

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer

By Hori Natsuko  

International Journal of Clinical Oncology, Vol. 18, Iss. 3, 2013-06 ,pp. : 435-438

Springer Publishing Company

Access to resources Recommend Favorite

FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study

By Kochi Mitsugu   Akiyama Yuji   Aoki Tatsuya   Hagiwara Ken   Takahashi Takao   Hironaka Katsuji   Teranishi Futoshi   Osuka Fumihiko   Takeuchi Masahiro   Fujii Masashi   Nakajima Toshifusa  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1097-1102

Springer Publishing Company

Access to resources Recommend Favorite

Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

By Rocha Lima Caio M.   Bayraktar Soley   Flores Aurea M.   MacIntyre Jessica   Montero Alberto   Baranda Joaquina C.   Wallmark John   Portera Chia   Raja Rajiv   Stern Howard   Royer-Joo Stephanie   Amler Lukas C.  

Cancer Investigation, Vol. 30, Iss. 10, 2012-12 ,pp. : 727-731

Informa Healthcare

Access to resources Recommend Favorite

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients

By  

Oncology Letters, Vol. 9, Iss. 2, 2015-01 ,pp. : 987-993

Spandidos Publications

Access to resources Recommend Favorite

Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study

By Santini Daniele   Vincenzi Bruno   Schiavon Gaia   Di Seri Marisa   Virzí Vladimir   Spalletta Bruno   Caricato Marco   Coppola Roberto   Tonini Giuseppe  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 613-620

Springer Publishing Company

Access to resources Recommend Favorite